Acadia Pharmaceuticals (ACAD)

Executive Summary

Acadia Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for underserved neurological disorders and rare diseases. Its lead product, Nuplazid (pimavanserin), is the only FDA-approved treatment for Parkinson's disease psychosis, providing a steady revenue stream. The company is expanding its pipeline by evaluating pimavanserin in additional indications, including intermittent explosive disorder (Phase 2) and autism spectrum disorder (Phase 2). Despite setbacks in schizophrenia and Rett syndrome programs, Acadia maintains a disciplined approach to clinical development. Key near-term value drivers include the completion of the Phase 2 trial of pimavanserin in autism spectrum disorder, with top-line data expected in early 2027. Acadia also has a Phase 2 trial ongoing in intermittent explosive disorder, though data are not anticipated until 2028. Successful results could significantly expand the addressable market for Nuplazid. Investor sentiment remains cautiously optimistic, supported by Nuplazid's commercial stability and the potential for label expansion in high-need indications.

Upcoming Catalysts (preview)

• Q1 2027Data readout from Phase 2 trial of pimavanserin in autism spectrum disorder50% success
• 2028Data readout from Phase 2 trial of pimavanserin in intermittent explosive disorder40% success